Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

10/04/2012 | 07:16pm US/Eastern

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
React to this article
Latest news on NOVARTIS AG
06:00a NOVARTIS : Heart failure treatment (Pr)ENTRESTO(TM) (LCZ696) shown to reduce the..
10/05DJEUROPE MARKETS : European Stocks Post Largest Gain Since August
10/05DJEUROPE MARKETS : European Stocks On Track For A Two-week High
10/05 NOVARTIS : Alcon receives FDA Approval for pre-loaded intraocular lens delivery ..
10/05 INDIVIOR : Says Sandoz Has Filed For Generic Version Of Suboxone
10/05DJEUROPE MARKETS : European Stocks On Track For A Two-week High
10/05 NOVARTIS : Alcon receives FDA Approval for pre-loaded intraocular lens delivery ..
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
10/02 NOVARTIS : FDA accepts Sandoz regulatory submission for a proposed biosimilar et..
10/01DJFDA Approves Bristol-Myers's Yervoy, Opdivo for Treatment of Melanoma -- Upda..
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials